The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010
Abstract
BACKGROUND: Human papillomavirus (HPV) vaccination was introduced into the routine immunization schedule in the United States in late 2006 for females aged 11 or 12 years, with catch-up vaccination recommended for those aged 13-26 years. In 2010, 3-dose vaccine coverage was only 32% among 13-17 year-olds. Reduction in the prevalence of HPV types targeted by the quadrivalent vaccine (HPV-6, -11, -16, and -18) will be one of the first measures of vaccine impact. METHODS: We analyzed HPV prevalence data from the vaccine era (2007-2010) and the prevaccine era (2003-2006) that were collected during National Health and Nutrition Examination Surveys. HPV prevalence was determined by the Linear Array HPV Assay in cervicovaginal swab samples from females aged 14-59 years; 4150 provided samples in 2003-2006, and 4253 provided samples in 2007-2010. RESULTS: Among females aged 14-19 years, the vaccine-type HPV prevalence (HPV-6, -11, -16, or -18) decreased from 11.5% (95% confidence interval [CI], 9.2-14.4) in 2003-2006 to 5.1% (95% CI, 3.8-6.6) in 2007-2010, a decline of 56% (95% CI, 38-69). Among other age groups, the prevalence did not differ significantly between the 2 time periods (P > .05). The vaccine effectiveness of at least 1 dose was 82% (95% CI, 53-93). CONCLUSIONS: Within 4 years of vaccine introduction, the vaccine-type HPV prevalence decreased among females aged 14-19 years despite low vaccine uptake. The estimated vaccine effectiveness was high.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A review of human carcinogens—Part B: biological agents
Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., Ghissassi, F. E., Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70096-8 · Cited by 2,935
de Sanjose, S., Quint, W. G., Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B., Tous, S., Felix, A., Bravo, L. E., Shin, H.-R., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70230-8 · Cited by 2,728
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa061741 · Cited by 2,055
Markowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., & Unger, E. R. (2007) · PsycEXTRA Dataset · doi:10.1037/e601292007-001 · Cited by 1,882
Self-citationPaavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61248-4 · Cited by 1,655
Le, M. (2007) · Medical Entomology and Zoology · Cited by 1,624
Prevalence of HPV Infection Among Females in the United States
Dunne, E. F., Unger, E. R., Sternberg, M., McQuillan, G., Swan, D. C., Patel, S. S., & Markowitz, L. E. (2007) · JAMA · doi:10.1001/jama.297.8.813 · Cited by 1,579
Self-citationVilla, L. L., Costa, R. L. R., Petta, C. A., Andrade, R. P., Paavonen, J., Iversen, O.-E., Olsson, S.-E., Høye, J., Steinwall, M., Riis-Johannessen, G., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603469 · Cited by 806
Design and estimation for the National Health Interview Survey, 1995-2004
Botman, S., & Moriarity, C. L. (2000) · Cited by 785
Brown, D. R., Kjaer, S. K., Sigurdsson, K., Iversen, O., Hernandez‐Avila, M., Wheeler, C. M., Perez, G., Koutsky, L. A., Tay, E. H., Garcia, P., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/597307 · Cited by 627
Wheeler, C. M., Castellsagué, X., Garland, S. M., Szarewski, A., Paavonen, J., Naud, P., Salmerón, J., Chow, S.-N., Apter, D., Kitchener, H., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70287-x · Cited by 507
Epidemiologic studies utilizing surveys: accounting for the sampling design.
Korn, E. L., & Graubard, B. I. (1991) · American Journal of Public Health · doi:10.2105/ajph.81.9.1166 · Cited by 490
Estimating Model-Adjusted Risks, Risk Differences, and Risk Ratios From Complex Survey Data
Bieler, G. S., Brown, G. G., Williams, R. L., & Brogan, D. J. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwp440 · Cited by 460
Dobson, S. R. M., McNeil, S., Dionne, M., Dawar, M., Ogilvie, G., Krajden, M., Sauvageau, C., Scheifele, D. W., Kollmann, T. R., Halperin, S. A., et al. (2013) · JAMA · doi:10.1001/jama.2013.1625 · Cited by 417
ASSESSING VACCINE EFFICACY IN THE FIELD
ORENSTEIN, W. A., BERNIER, R. H., & HINMAN, A. R. (1988) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036023 · Cited by 385
Hariri, S., Unger, E. R., Sternberg, M., Dunne, E. F., Swan, D., Patel, S., & Markowitz, L. E. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir341 · Cited by 380
Self-citationQuadrivalent Human Papillomavirus Vaccine
Gellin, B., Modlin, J. F., Barr, E., & Tamms, G. (2007) · Clinical Infectious Diseases · doi:10.1086/520654 · Cited by 330
Chaturvedi, A. K., Katki, H. A., Hildesheim, A., Rodríguez, A. C., Quint, W., Schiffman, M., Van Doorn, L.-J., Porras, C., Wacholder, S., Gonzalez, P., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq139 · Cited by 329
Kreimer, A. R., Rodriguez, A. C., Hildesheim, A., Herrero, R., Porras, C., Schiffman, M., González, P., Solomon, D., Jiménez, S., Schiller, J. T., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr319 · Cited by 324
Fall in Human Papillomavirus Prevalence Following a National Vaccination Program
Tabrizi, S. N., Brotherton, J. M. L., Kaldor, J. M., Skinner, S. R., Cummins, E., Liu, B., Bateson, D., McNamee, K., Garefalakis, M., & Garland, S. M. (2012) · Journal of Infectious Diseases · doi:10.1093/infdis/jis590 · Cited by 264
Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms
Stanley, M., Lowy, D. R., & Frazer, I. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.110 · Cited by 262
Read, T. R. H., Hocking, J. S., Chen, M. Y., Donovan, B., Bradshaw, C. S., & Fairley, C. K. (2011) · Sexually Transmitted Infections · doi:10.1136/sextrans-2011-050234 · Cited by 249
Wheeler, C. M., Kjaer, S. K., Sigurdsson, K., Iversen, O., Hernandez‐Avila, M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., García, P., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/597309 · Cited by 242
Chesson, H. W., Ekwueme, D. U., Saraiya, M., Watson, M., Lowy, D. R., & Markowitz, L. E. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.056 · Cited by 205
Self-citationVaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction
Kahn, J. A., Brown, D. R., Ding, L., Widdice, L. E., Shew, M. L., Glynn, S. M., & Bernstein, D. I. (2012) · PEDIATRICS · doi:10.1542/peds.2011-3587 · Cited by 143
What’s the Story? Expectations for Oral Case Presentations
Dell, M., Lewin, L. O., & Gigante, J. (2012) · PEDIATRICS · doi:10.1542/peds.2012-1014 · Cited by 104
Prevalence and Clustering Patterns of Human Papillomavirus Genotypes in Multiple Infections
Chaturvedi, A. K., Myers, L., Hammons, A. F., Clark, R. A., Dunlap, K., KISSINGER, P. J., & Hagensee, M. E. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0465 · Cited by 101
Post-licensure monitoring of HPV vaccine in the United States
Markowitz, L. E., Hariri, S., Unger, E. R., Saraiya, M., Datta, S., & Dunne, E. F. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.02.019 · Cited by 98
Self-citationFlagg, E. W., Schwartz, R. S., & Weinstock, H. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.301182 · Cited by 95
Dorell, C., Jain, N., & Yankey, D. (2011) · Public Health Reports · doi:10.1177/00333549111260s208 · Cited by 94
Dunne, E. F., Sternberg, M., Markowitz, L. E., McQuillan, G. M., Swan, D., Patel, S. S., & Unger, E. R. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir342 · Cited by 67
Self-citationCarozzi, F., Ronco, G., Gillio‐Tos, A., Marco, L. D., Mistro, A. D., Girlando, S., Franceschi, S., Plummer, M., & Vaccarella, S. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.010 · Cited by 63
A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD®
Bonanni, P., Cohet, C., Kjær, S. K., Latham, N. B., Lambert, P., Reisinger, K. S., & Haupt, R. M. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.04.070 · Cited by 61
Vaccarella, S., Franceschi, S., Herrero, R., SCHIFFMAN, M. H., Rodríguez, A. C., Hildesheim, A., Burk, R. D., & Plummer, M. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir286 · Cited by 55
Clustering of Human Papillomavirus (HPV) Types in the Male Genital Tract: The HPV in Men (HIM) Study
Vaccarella, S., Plummer, M., Franceschi, S., Gravitt, P. E., Papenfuss, M. R., Smith, D. C., Villa, L. L., Lazcano-Ponce, E. C., & Giuliano, A. R. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir595 · Cited by 28
Cited by
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Sexually Transmitted Diseases Treatment Guidelines, 2010
(2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,076
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
Feng, R., Zong, Y., Cao, S., & Xu, R. (2019) · Cancer Communications · doi:10.1186/s40880-019-0368-6 · Cited by 1,625
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
Drolet, M., Bénard, É., Pérez, N., Brisson, M., Ali, H., Boily, M.-C., Baldo, V., Brassard, P., Brotherton, J. M. L., Callander, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30298-3 · Cited by 1,384
Self-citation
Metadata
- Authors
- Markowitz, L. E., Hariri, S., Lin, C., Dunne, E. F., Steinau, M., McQuillan, G., & Unger, E. R.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-01
- Volume
- 208
- Issue
- 3
- Pages
- 385-393
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2102786052
- Cited by
- 521
- References
- 36
- FWCI
- 59.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.